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Abstract  
Ethnopharmacological relevance 
Globally 387 million people currently have diabetes and it is projected that this condition will be the 
7th leading cause of death worldwide by 2030. As of 2012, its total prevalence in Central America 
(8.5%) was greater than the prevalence in most Latin American countries and the population of this 
region widely use herbal medicine. The aim of this study is to review the medicinal plants used to 
treat diabetes and its sequelae in seven Central American countries: Belize, Costa Rica, El Salvador, 
Guatemala, Honduras, Nicaragua and Panama. 
 
Materials and Methods 
We conducted a literature review and extracted from primary sources the plant use reports in 
traditional remedies that matched one of the following disease categories: diabetes mellitus, kidney 
disease, urinary problems, skin diseases and infections, cardiovascular disease, sexual dysfunctions, 
visual loss, and nerve damage. Use reports were entered in a database and data were analysed in 
terms of the highest number of use reports for diabetes management and for the different sequelae. 
We also examined the scientific evidence that might support the local uses of the most reported 
species. 
 
Results 
Out of 535 identified species used to manage diabetes and its sequelae, 104 species are used to 
manage diabetes and we found in vitro and in vivo preclinical experimental evidence of 
hypoglycaemic effect for 16 of the 20 species reported by at least two sources. However, only seven 
of these species are reported in more than 3 studies: Momordica charantia L., Neurolaena lobata (L.) 
R. Br. ex Cass., Tecoma stans (L.) Juss. ex Kunth, Persea americana Mill.,  Psidium guajava L., 
Anacardium occidentale L. and Hamelia patens Jacq.  Several of the species that are used to manage 
diabetes in Central America are also used to treat conditions that may arise as its consequence such 
as kidney disease, urinary problems and skin conditions. 
 
Conclusion 
This review provides an overview of the medicinal plants used to manage diabetes and its sequelae 
in Central America and of the current scientific knowledge that might explain their traditional use. In 
Central America a large number of medicinal plants are used to treat this condition and its sequelae, 
although relatively few species are widely used across the region. For the species used to manage 
diabetes, there is variation in the availability and quality of pharmacological, chemical and clinical 
studies to explain traditional use.  
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1. Introduction 
Diabetes mellitus is a group of metabolic diseases, characterised by high blood glucose levels 
(hyperglycaemia) that occurs when there is insufficient insulin secretion from the pancreas, or there 
are defects in its action, or both. The WHO defines diabetes as having a fasting plasma glucose value 
≥ 7.0 mmol/L (126 mg/dl) or being on medication for raised blood glucose (WHO, 2010). The 
majority of diabetes cases fall into two broad categories: type 1 diabetes (T1D), previously known as 
insulin-dependent, or juvenile onset diabetes, where there is deficient insulin production; and type 2 
diabetes (T2D), previously known as non-insulin dependent or adult-onset diabetes, which accounts 
for 90% of all diabetes cases, and results from the body’s ineffective use of insulin (American 
Diabetes Association, 2004; WHO, 2015). Although previously only seen in adults, T2D is now 
occurring in children. There are other categories of diabetes, including gestational diabetes and rarer 
forms of genetic or acquired diabetes (WHO 2015). 
According to the International Diabetes Federation, globally 387 million people currently have 
diabetes (IDF, 2014), with 80% of adult deaths from diabetes occurring in low and middle income 
countries (IDF, 2014; WHO, 2015). It is projected that diabetes will be the 7th leading cause of death 
worldwide by 2030 (WHO, 2015). By 2035, the number of diabetes cases worldwide is expected to 
increase to 592 million. The number of people with diabetes in the South and Central America 
Region (SACA) is projected to increase by 60% by 2035, with an average prevalence of diabetes 
expected to reach 9.8% (Aschner et al., 2014; IDF, 2014). The top five countries with the highest 
prevalence in 2013 in the SACA Region include two countries in the Caribbean Islands and three 
countries from Central America: Nicaragua (12.45%), Guatemala (10.87%), and El Salvador (10.50%). 
A 2012 epidemiologic study also found that the total prevalence of diabetes of 8.5% in the combined 
Central America sample studied was greater than the prevalence in most Latin American countries. 
Since the population of Central America is relatively young, the future burden of the disease in the 
next decades is likely to increase substantially (Barcelo et al., 2012).  
The indigenous populations in this region are particularly at risk from diabetes, resulting from 
marginalisation and lack of access to care and prevention, in addition to dramatic lifestyle changes, 
including nutrition transition to a diet high in refined carbohydrates (Aschner et al., 2014). Studies 
have shown that globally, indigenous populations suffer disproportionately from T2D and related 
complications, regardless of their geographic region (Ferrier et al., 2014; Naqshbandi et al., 2008).  
In addition to risk of death from hyperglycaemic crisis, chronic hyperglycaemia from diabetes can 
lead to many long term health issues. These sequelae include: cardiovascular disease (CD), and an 
increased risk of heart attack or stroke; chronic kidney disease (KD) leading to end-stage renal 
disease; urinary problems (UP); peripheral neuropathy (nerve damage, ND); skin infections (SI), 
especially foot ulcers, that are difficult to heal, with the eventual need for lower-extremity 
amputation; retinopathy leading to vision loss (VL); and sexual dysfunction (SD). Over 70% of people 
with T2D may die from cardiovascular disease  (Laakso, 2010). Chronic kidney disease, mainly the 
result of diabetes and hypertension, is the fastest growing non-communicable disease. There are 
few medicines available to specifically treat diabetic kidney disease. Globally, median years of life 
lost to chronic kidney disease rose by 90% between 1997 and 2013, compared with a 67% rise in 
years of life lost to diabetes (The Lancet Diabetes & Endocrinology, 2015).  
Compared to people who do not have diabetes, people with diabetes require at least two to three 
times the health-care resources, and may account for up to 15% of national health care budgets 
(WHO, 2010). Clearly, diabetes is both a huge health and economic burden globally, and notably for 
low and middle income countries including those in Central America. 
In this paper we present the results of a review of medicinal plants used to treat diabetes and its 
sequelae in seven Central American countries (Belize, Costa Rica, El Salvador, Guatemala, Honduras, 
Nicaragua and Panama). The data are analysed in terms of the highest number of use reports for the 
management of diabetes and for each of the different sequelae. The regional approach we have 
taken provides a useful overview and indication of which plants may provide benefit in the 
management of diabetes and its sequelae. Whilst the aim of this review is to capture use data for 
species indicative of having relevance to diabetes in the selected Central American countries, we 
also explore the scientific evidence that appears to support the local uses of the most reported 
species. It is beyond the scope of this review to extensively discuss the available data on the 
pharmacological activities and clinical studies for all of the recorded species. However, where 
promising data are available and there is knowledge of the phytochemical constituents that might 
aid our understanding of the scientific basis for traditional use (and potential use), these are briefly 
discussed. 
 
2. Methods 
For the purpose of this review we defined Central America as the region including Belize, Guatemala, 
Honduras, El Salvador, Nicaragua, Costa Rica and Panama. We conducted a literature review by 
searching for combination of keywords such as the name of the country and “medicinal plants”, 
“ethnobotany”, “ethnopharmacology”, “ethnomedicine”, and “herbal medicine” in the databases 
SCOPUS, Web of Science, Google Scholar, and Pubmed. The search was conducted using both English 
and Spanish keywords. We also conducted such searches on single journals such as Journal of 
Ethnopharmacology, and the Journal of Ethnobiology and Ethnomedicine. To cover some of the gaps 
in the literature found during these searches, we conducted a literature research of books held at 
the library of the Royal Botanic Gardens Kew, including books published in English, Spanish and 
French. We included in our review only studies publishing primary data validated by the collection of 
voucher specimens to avoid double counting (Leonti, 2011) use reports generated from the same 
research. This included 24 journal papers, 1 conference proceeding, 1 PhD thesis, and 6 books (total 
32 sources used). When sources included both primary and secondary data, such as for example in 
Balick and Arvigo (2015), and these were clearly differentiated in the text, then we included only the 
primary data in our database.    
From the literature included in this study we extracted the use-reports that matched one of the 
following disease categories: diabetes mellitus, kidney disease, urinary problems, skin diseases and 
infections, cardiovascular disease, sexual dysfunctions, visual loss, and nerve damage. These use 
reports were entered in a bespoke Access relational database [see supplementary material in 
(Giovannini et al., submitted)], including the disease category, the reference, the name of the 
species, and how it is used. We excluded from our database taxa that were not identified at species 
level.   
Name validation 
Scientific names of plants that met our criteria for assessment in this review, along with associated 
data, were compiled in a bespoke Access relational database. The majority of these names were 
checked manually against The Plant List Version 1.1 (TPL) at point of entry. TPL was created through 
merging of Kew’s various name datasets (both published and unpublished), along with major 
datasets supplied by Kew’s partners, including Missouri Botanical Garden (US). As TPL was 
synthesised automatically, rather than compiled by human specialists, the reliability of TPL is 
variable, so records are assigned one of three confidence levels. Of the 607 scientific plant names 
checked we found 6% with a low confidence level and the remaining 94% with a high or medium 
confidence level.  On completion of data entry, the entire dataset of scientific plant names was 
evaluated automatically against TPL for precision, confidence level, taxonomic currency, and 
synonymy. Names that did not match due to typographic errors were found using ‘fuzzy’ searches, 
setting the Levenshtein distance to 2. After name validation was carried out the database included 
537plant taxa (for a total of 535 plant species, as 2 taxa are infraspecific), and 1055 use reports 
within the categories included in this review after excluding secondary data and taxa that were not 
identified at species level. 
 
 
3. Results and discussion 
3.1 Plant families with species used to treat diabetes and its sequelae in Central America 
The families with more recorded species to manage diabetes mellitus in Central America are 
Asteraceae (7 species), Fabaceae (7 species), Rubiaceae (6 species), Euphorbiaceae (6 species), 
Bignoniaceae (5 species), Myrtaceae (5 species), Rutaceae (5 species), Amaranthaceae (4 species), 
and Solanaceae (3 species). Some of the known phytochemical classes that occur in these families 
and how this knowledge might contribute to our understanding of the relevance of these particular 
families to diabetes are summarised below. 
Of 656 flowering plants identified as associated with traditional uses relevant to diabetes in a 
previous study, a high proportion of the 437 genera, representing 111 families, were from the 
asterids and rosids (Simmonds and Howes, 2006). There is chemical diversity amongst the rosids, 
and members of the Fabaceae are reported to include flavonoids, alkaloids and triterpene saponins   
amongst their constituents (Leonti et al., 2003; Simmonds and Howes, 2006). Simmonds and Howes 
(2006) identified 81 species within the Fabaceae with reported hypoglycaemic activity (Simmonds 
and Howes 2006). Flavonoids from the Fabaceae have been widely studied and include those with 
mechanistic effects relevant to diabetes, as reviewed in Simmonds and Howes (2006).  
It has been estimated that almost 50% of the plant-derived natural products that are 
pharmaceutically and biologically significant are alkaloids (Cordell et al., 2001). Therefore knowledge 
of their taxonomic distribution can assist with our understanding of the traditional uses of alkaloid-
containing species as medicines. Similarly to the Fabaceae, members of the Rubiaceae also include 
many alkaloid containing species; in the Rubiaceae these include those of the monoterpenoid-indole 
class; other phytochemicals reported for this family include iridoids and anthraquinones (De Kuca et 
al., 2014; Han et al., 2001). Solanaceae members contain a wide range of biologically active alkaloids, 
including tropane, pyrrolidine, glycoalkaloid and steroidal alkaloid classes (Cadenas et al., 2015; 
Griffin and Lin, 2000; Pomilo et al., 2008). Although often relevant for biological activities with 
therapeutic effects, alkaloids may also be associated with toxic effects, which should be considered 
when also evaluating traditional uses and the traditional methods of preparation. Members of the 
Euphorbiaceae also contain alkaloids (including the tropane class), in addition to diterpenes and 
polyphenols, whilst some members also contain triterpenes and cyanogenic glycosides (Griffin and 
Lin, 2000; Leonti et al., 2003; Tanaka and Matsunaga, 1999). Polyphenols have been linked to 
beneficial effects for the management of diabetes such as reduced absorption of dietary 
carbohydrate, regulation of carbohydrate metabolism and stimulation of insulin secretion 
(Bahadoran et al., 2013).  Intake of polyphenols is also associated with favourable effects on risk 
factors for type 2 diabetes (Simmonds and Howes, in press). 
Asteraceae and Fabaceae are both large plant families containing a wide variety of phytochemical 
classes. Members of the Asteraceae are reported to contains polyacetylenes, sesquiterpene 
lactones, monoterpenes, diterpenes, phenolic compounds (including flavonoids) and alkaloids 
(including those of the pyrrolizidine class); the latter have often be associated with hepatotoxicity 
(Heinrich et al., 1998; Leonti et al., 2003; Roeder, 2000). The bitter phytochemicals present in some 
Asteraceae have been suggested to be linked with increased experimentation from local people 
linking bitter taste to medical properties (Casagrande 2002; Heinrich et al., 1998); this is especially 
true when people look for plants to manage diabetes (Giovannini personal communication). Several 
studies show this plant family is often overrepresented in plant pharmacopoeias (Amiguet et al., 
2006; Leonti et al., 2003; Moerman 1996; Thomas et al., 2009). Sesquiterpene lactones, including 
those from Neurolaena species have been associated with anti-inflammatory activity (McKinnon et 
al., 2014; Walshe-Roussel et al., 2013), although this compound class has not been associated with 
hypoglycaemic effects in some studies (Davis, 1997) (see section 3.2). 
Genera in the Myrtaceae are often associated with volatile oil production, with many species 
containing monoterpenes as the major volatile oil constituents (Stefanello et al., 2011). Alkaloids are 
reported less frequently in this family. Members of the Rutaceae also produce volatile oils, alkaloids 
of various classes, coumarins and triterpenoids (Epifano et al., 2015; Jing et al., 2015). Many plant 
volatile oils have been associated with antimicrobial effects, including those from members of the 
Myrtaceae (Stefanello et al., 2011) and Rutaceae (Chintaluri et al., 2015). Antimicrobial effects, due 
to the volatile oil constituents, might provide some explanation for traditional uses for skin 
infections. Members of the Amaranthaceae also produce volatile oils, in addition to betalains, 
phenolic compounds and terpenoids, including triterpene saponins that have been associated with 
anti-diabetic effects (Mroczek, 2015). Triterpene from various species have been associated with 
mechanistic effects relevant to diabetes, as reviewed in Simmonds and Howes (2006).  Members of 
the Bignoniaceae have been reported to contain iridoids and phenylpropanoids; both compound 
classes are reported in Tecoma species (De Luca et al., 2014; Guiso et al., 1997). Alkaloids are 
reported less frequently in this family, although some alkaloids from Tecoma species have been 
associated with hypoglycaemic effects (see section 3.2). 
3.2 Plant species used to treat diabetes and its sequelae in Central America 
In this section we review our findings at species level and we discuss current scientific evidence that 
might explain the uses of the most reported plant species to manage diabetes and its sequelae. 
Table 1 shows the plant species reported in at least two sources as remedies to manage diabetes by 
the local population and whether these species are reported also to treat some of the sequelae of 
diabetes such as kidney disease, urinary problems, vision loss, cardiovascular problems, and skin 
conditions.  Table 2 shows the species used to treat skin conditions, Table 3 shows species reported 
as treatments for kidney disease, and Table 4 shows the species used to treat urinary complaints. 
Figure 1 shows the species with a high number of use reports for all the disease categories 
considered in this review. We do not present tables for the species reported as treatments for 
cardiovascular disease, vision loss and sexual dysfunction as we found that relatively few species 
were reported for these use categories.     
 Figure 1. Species with highest number of use reports for the management of diabetes and the 
treatment of its sequelae. CD= cardiovascular disease, DM=diabetes, KD=kidney disease, SI=skin 
conditions, VL=vision loss.  
 
Out of the 104 species that we found are used to manage diabetes in Central America, the species 
with at least 3 use reports were: Momordica charantia L., Neurolaena lobata (L.) R. Br. ex Cass., 
Tecoma stans (L.) Juss. ex Kunth, Persea americana Mill.,  Psidium guajava L., Anacardium 
occidentale L. and Hamelia patens Jacq.  
Momordica charantia L. is grown and is used to treat diabetes by indigenous and local communities 
in tropical areas of Asia, South-America, Central America, Mexico, India, Africa, and the Caribbean 
(Grover and Yadav 2004; Leung et al., 2009). Its hypoglycaemic properties have been shown in 
several animal studies, although few trials on humans have been conducted and there is a lack of 
randomised controlled trials (RCTs) that demonstrate its efficacy; there are more data for the fruits 
compared to other plant parts (Ooi et al., 2010; Yeh et al., 2003). We found that this species was 
reported independently as a treatment for diabetes in 9 ethnobotanical studies conducted in Central 
America and the leaf was the most commonly reported plant part used (in 7 out of 9 of reports).  
Pharmacological and phytochemical studies have focused on the fruits of this species (which are 
used in other traditional practices of medicine) and have revealed that cucurbitane-type 
triterpenoids in particular show mechanistic effects relevant to diabetes (Chang et al., 2015; Nhiem 
et al., 2010; Tan et al., 2008). Interestingly, the stems of this species also contain triterpenoids, 
including 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al, which was previously isolated from the 
fruits and hypoglycaemic when tested in alloxan-induced diabetic mice (Cheng et al., 2008). The 
stem triterpenoids [including 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al] also modulated 
insulin resistance in vitro, which was associated with activation of AMPK, enhancing tyrosine 
phosphorylation of IRS-1 to modulate the insulin signalling pathway (Cheng et al., 2008). Charantin 
(a mixture of steroidal saponins) from the fruits of M. charantia is reported as hypoglycaemic 
(Krawinkel and Keding, 2006), yet it occurs at higher concentrations in the leaves (El-Said and Al-
Barak, 2011). Thus, the triterpenoids and charantin that occur in the leaves (the most commonly 
reported plant part in this study) and stems of M. charantia appear to provide some scientific basis 
for the traditional use for diabetes. 
We also found 5 independent reports of M. charantia to treat skin conditions in Central America. 
Indeed, several studies associate this species with broad-spectrum anti-microbial activity   (Ooi et al., 
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2010; Grover and Yadav, 2004), which could be linked to some of its traditional uses.   However, the 
fruit extracts have shown more potent antibacterial activity than leaf extracts (Supraja and Usha, 
2013). 
Neurolaena lobata (L.) R. Br. ex Cass is a herb found in Mexico, Central America, the Caribbean, and 
North South-America (GBIF, 2015a). We found six reports of the use of this species to manage 
diabetes in Central America (Balick and Arvigo, 2015; Barrett, 1994; Cruz and Andrade-Cetto, 2015; 
Ferrier, 2014; Girón et al., 1991; Pöll 1997).  The traditional use of N. lobata to manage diabetes has 
been reported in Mexico and in the Caribbean (Andrade-Cetto and Heinrich, 2005; Soumyanath, 
2005) and its leaf extracts significantly decrease blood glucose in mice  (Gupta et al., 1984). 
However, no specific antidiabetic compounds have been isolated from this species to date, and RCTs 
are also lacking. Our review shows that N. lobata is also widely used in Central America to treat skin 
conditions. The results of animal studies appear to support the healing activity of this species in 
cutaneous wounds (Nayak et al., 2014) and it also has antimicrobial activity (Nayak et al., 2014). 
Extracts of N. lobata showed anti-ulcerogenic and anti-nociceptive effects (Gracioso et al., 2000; 
Gracioso et al., 1998). Furthermore, other studies revealed that extracts from this species have anti-
inflammatory activity and several sesquiterpene lactones have been identified that mediate this 
effect (McKinnon et al., 2014; Walshe-Roussel et al., 2013).   
Tecoma stans (L.) Juss. ex Kunth, a native of the Americas, is a shrub or small tree widely distributed 
in the tropics  and subtropics  (Pelton, 1964). It is used in Mexico and Central America to manage 
diabetes and treat urinary disorders (Aguilar-Santamaría et al., 2009). We found six reports of its use 
in the management of diabetes in Guatemala and in El Salvador (Cruz and Andrade-Cetto, 2015; 
Girón et al., 1991; Gonzalez-Ayala, 1994; MacVean, 2006; Nicolas, 1999; Pöll, 1997). Accordingly, its 
extracts have hypoglycaemic activity in animal models of diabetes (Román-Ramos et al., 1990). Leaf 
extracts inhibit intestinal α-glucosidase, modulate postprandial hyperglycaemia and reduce 
triglycerides and cholesterol in vivo (Aguilar-Santamaría et al., 2009), which may provide some 
scientific explanation for the traditional use. Studies report the alkaloid tecomine from the leaves of 
this species to be hypoglycaemic in vivo, although it has low stability (Hammouda and Khalafallah, 
1971). Other studies concluded that alkaloids, including tecomine and tecostanine, were not 
hypoglycaemic in vivo (Costantino et al., 2003). Therefore, traditional preparations would need to be 
further evaluated to determine the stability of these alkaloids and their role in explaining the 
scientific basis for the use of this in diabetes. 
We found 5 reports of uses of Persea americana Mill. to manage diabetes in Central America, in 
most cases the plant part used was the leaf but there are also reports of the use of the bark and the 
seed (Balick and Arvigo 2015; Coe and Anderson, 1999; Coe and Anderson 1996; Cruz and Andrade-
Cetto 2015; Gonzalez-Ayala, 1994). We also found reports of the use of P. americana to treat kidney 
disease and urinary problems. Animal studies showed that extracts of P. americana have 
hypoglycaemic properties, improve kidney function and blood pressure, and reduce cholesterol and 
triglycerides levels (Antia et al., 2005; Brai et al., 2007; Ezejiofor et al., 2013; Gondwe et al., 2008; 
Imafidon and Amaechina 2010). A hydroalcoholic extract of the leaves was suggested to be 
hypoglycaemic in vivo, via regulation of glucose uptake in liver and muscles via PKB/Akt activation 
(Lima et al., 2012). Preliminary clinical trials showed that dietary consumption of this species might 
maintain cardiovascular health (Dreher and Davenport, 2013) due to its antihypercholesterolaemic 
and antihyperlipidaemic activity (Lim, 2012), although RCTs specifically investigating the anti-diabetic 
properties of this species are lacking.   
Psidium guajava L. is a small tree used medicinally in most tropical and subtropical areas. We found 
4 studies reporting its use to manage diabetes in Guatemala (Cruz and Andrade-Cetto, 2015; Girón 
et al., 1991; MacVean 2006; Pöll, 1997). The use of this species to manage diabetes has also been 
reported in South Africa and in the Caribbean (Gutiérrez et al., 2008).   Studies conducted on animals 
have shown that extracts from P. guajava lower blood glucose (Mukhtar et al., 2006; Mukhtar et al., 
2004; Oh et al., 2005; Ojewole 2005; Ruiz et al., 2011; Shen et al., 2008). This species is also an anti-
LDL glycative agent, which make it potentially useful in the prevention of cardiovascular and 
neurodegenerative diseases (Gutiérrez et al., 2008). Phenolic compounds, including gallic acid, 
catechin and quercetin, are considered to contribute to the anti-glycation effects of leaf extracts 
(Wu et al., 2009). Furthermore, the flavonols quercetin, kaempferol and myricetin showed inhibitory 
activities against sucrase, maltase and α-amylase in vitro (Wang et al., 2010). Flavonol glycosides 
(peltatoside, hyperoside, isoquercitrin and guaijaverin in particular) from the leaves of this species 
also inhibited dipeptidyl peptidase IV, a key enzyme for blood glucose homeostasis (Eidenberger et 
al., 2013), which might provide some scientific explanation for the traditional use of the leaves for 
diabetes. 
Our results suggest that in Central America this species is also widely used for skin conditions, with 
six studies conducted in Belize, Nicaragua and Guatemala reporting the use of this species for this 
use category. This could be related to the reported antimicrobial, analgesic and anti-inflammatory 
properties of P. guajava (Gutiérrez et al., 2008). Known antibacterial compounds in the leaves 
include the flavonol glycoside guaijaverin (Prabu et al., 2006) and the benzophenone glycoside, 
guajaphenone A (Ukwueze at al., 2015), whilst quercetin and the 3-O-arabinoside showed anti-
quorum sensing activity (Vasavi et al., 2014). Thus, there appears to be some scientific evidence to 
explain the use of the leaves of this species in particular for both internal and external use. The 
range of biological activities demonstrated to date for extracts and individual constituents suggest 
that ‘polyvalency’ is important for the reputed benefits of this species for diabetes, such that several 
different constituents may act via different modes of action to produce an overall effect on diabetes 
parameters. 
Anacardium occidentale L., known as cashew tree, is widely distributed in Central America and in 
tropical South America but also widely cultivated in some parts of Africa and in Asia (GBIF 2015b). 
Several Central American ethnobotanical studies report that the bark and leaf of this species is used 
to manage diabetes mellitus (Duke 1986; Cruz and Andrade-Cetto 2015; Gupta et al., 1979), skin 
conditions (Barrett 1994; Coe 2008; Coe and Anderson, 1999; Coe and Anderson, 1996; Coe et al., 
1997), kidney disease and urinary problems (Gonzalez-Ayala, 1994). Animal studies on extracts of A. 
occidentale showed a hypoglycaemic effect (Esimone et al., 2001; Ojewole, 2003; Olatunji et al., 
2005; Sokeng et al., 2001), in addition to anti-inflammatory activity (Mota et al., 1985). Tedong et al. 
(2006) showed that an extract of A. occidentale has a renal protective effect on streptozotocin 
induced diabetic rats. It is suggested that stigmast-4-en-3-ol and stigmast-4-en-3-one contribute to 
the hypoglycaemic effect of bark extracts, since these steroidal compounds were associated with 
producing hypoglycaemia in vivo (Alexander-Lindo et al., 2004).  
Hamelia patens Jacq. is a native shrub of American subtropics and tropics. The use of a decoction of 
the leaves of H. patens to manage diabetes was reported in 3 studies conducted in Belize, 
Guatemala and El Salvador (Balick and Arvigo, 2015; Cruz and Andrade-Cetto, 2015; Gonzalez-Ayala, 
1994). There is a lack of studies on H. patens potential antidiabetic properties, however one study 
suggests that the extract of this species is hypoglycaemic (Pandurangan et al., 2013). An ethanol 
extract of the leaves was antinociceptive in vivo (Alonso-Castro et al., 2015), which might suggest a 
rationale for traditional use to alleviate symptoms, rather than target hyperglycaemia.  We found 
that this species is also widely used to treat skin conditions with 5 studies from Belize, Nicaragua and 
El Salvador documenting uses such as such as skin infections, rashes and sores. Previous studies 
showed that extracts of this species have anti-microbial (Camporese et al., 2003), anti-inflammatory 
(Sosa et al., 2002) and wound healing activities (Gomez-Beloz et al., 2003). More studies are needed 
to understand more about any pharmacological basis for the traditional use for diabetes and the 
constituents that may mediate any relevant mechanistic effects.     
Bursera simaruba (L.) Sarg is a tree growing in Mexico, Central America, the Caribbean, and Northern 
South America. We found 2 studies, both from Belize, reporting the use of B. simaruba in the 
management of diabetes mellitus (Balick and Arvigo, 2015; Ferrier, 2014). Interestingly, this species 
is also used in Mexico to manage diabetes (Andrade-Cetto and Heinrich, 2005) and it is widely used 
in Central America to treat skin conditions, kidney disease and urinary problems (Balick and Arvigo, 
2015; Coe, 2008; Coe et al., 1997; Coe and Anderson, 1996; Duke, 1986; Gupta et al., 2005; Kufer et 
al., 2005; MacVean, 2006). Animal studies showed anti-microbial and anti-inflammatory activity of 
the extracts (Bork et al., 1996; Camporese et al., 2003; Noguera et al., 2004; Sosa et al., 2002) but 
there is a lack of studies investigating its anti-diabetic properties. There is also a lack of research on 
the phytochemical constituents that may mediate effects relevant to diabetes. One study has 
suggested that methyl-β-peltatin A may contribute to the anti-inflammatory activity of the leaves 
(Noguera et al., 2004). Considering its use in Mexico and in Central America for the management of 
diabetes and the treatment of its sequelae, this species is a good candidate for further research to 
understand more about any scientific basis for its traditional use.      
 
Carica papaya L. is a widely cultivated tropical tree native of the Americas. We found reports for the 
use of C. papaya in the management of diabetes in Belize (Balick and Arvigo, 2015) and Guatemala 
(Cruz and Andrade-Cetto, 2015). Moreover the use of this species to treat skin conditions was 
mentioned in eight studies in Central American countries including Belize, Panama, El Salvador and 
Nicaragua. Pharmacological studies show that extracts of the seeds and leaves of this species have 
hypoglycaemic, hypolipidaemic and wound healing activities in experimentally induced diabetic rats 
(Adeneye et al., 2009; Juárez-Rojop et al., 2012; Maniyar and Bhixavatimath, 2012; Nayak et al., 
2007; Sasidharan et al., 2011). Although mechanistic effects relevant to diabetes are reported for C. 
papaya, the compounds that mediate these effects have not been widely investigated and more 
research is needed to understand the constituents that might explain the pharmacological basis for 
use. Interestingly, Balick and Arvigo (2015) report the use of the root of this species in the 
management of diabetes in a decoction with Chamaesyce hypericifolia (L.) Millsp. and Capraria 
biflora L. or in another mixture with Euphorbia armourii Millsp. and wood from Pinus caribaea var. 
hondurensis.  
Bixa orellana L. is a native shrub from the Americas that is now widely cultivated in tropical and 
subtropical areas. We found a study conducted in Guatemala (Girón et al., 1991) and one in Belize 
(Ferrier 2014) reporting its use to manage diabetes. Studies conducted in Nicaragua (Coe, 2008) and 
Belize (Balick and Arvigo, 2015)  also reports its use to treat skin conditions and for urinary problems 
(Balick and Arvigo, 2015).  Studies in vivo revealed extracts from its seed can have both 
hypoglycaemic or hyperglycaemic activity, depending on how the extract is prepared  (Morrison et 
al., 1990; Quanico et al., 2008; Russell et al., 2008) in addition to a hypolipidaemic effect (Ferreira et 
al., 2013). One study reports the carotenoids bixin and norbixin, from B. orellana seeds, to have 
opposing effects on glycaemia, lipidaemia and oxidative stress in streptozotocin-induced diabetic 
rats (Roehrs et al., 2014). Thus, more knowledge on the traditional preparations and their 
differences in chemical constituents might aid our understanding of the scientific basis to explain 
traditional use for diabetes, to enable direct correlation with, and greater understanding of, the 
traditional methods of preparation.   B. orellana extracts are reported to contain a mixture of 
carotenoids, including β-carotene, which inhibit the expression of NADPH oxidase subunits and 
increase the expression of antioxidant enzymes in neutrophils in an animal model of diabetes 
(Rossoni-Júnior et al., 2012), suggesting potential amelioration of neutrophil dysfunction that can 
occur in diabetes. A clinical trial showed beneficial effects of an extract of this species administered 
as an adjunct on type-2 diabetes patients (Herrera-Arellano et al., 2004). However, more RCTs are 
needed to enable more firm conclusions on efficacy, performed with chemically-characterised 
extracts that reflect preparations that mediate hypoglycaemic effects (rather than the 
hyperglycaemic activity reported for some extracts, as described above). 
Cecropia obtusifolia Bertol. is a tree growing in tropical forest and found in Mexico and Central 
America. Its use to manage diabetes was reported in Guatemala (Cruz and Andrade-Cetto, 2015) and 
in Belize (Balick and Arvigo, 2015). Extracts of this species were found to have a hypoglycaemic 
effect and Andrade-Cetto (2001) identified chlorogenic acid as one of the active hypoglycaemic 
compounds in the extract (Andrade-Cetto and Wiedenfeld, 2001). Other constituents that may 
contribute to the hypoglycaemic effects of extracts, and their specific modes of action, are yet to be 
determined. Two clinical trials showed beneficial effects of extract of this species, including when 
administered as an adjunct, in type-2 diabetes patients (Herrera-Arellano et al., 2004; Revilla-
Monsalve et al., 2007). Furthermore, Gonzalez-Ayala (1994) reports the use of this species in El 
Salvador to treat kidney diseases and Coe (2008) reports its use among the Rama of Nicaragua to 
treat skin conditions. A pharmacological study showed that this species has anti-inflammatory and 
analgesic properties that could be related to its traditional use (Pérez-Guerrero et al., 2001). 
Interestingly, we found also a report of the use in Central America of the related C. peltata to 
manage diabetes mellitus (Balick and Arvigo, 2015), to treat kidney diseases and to treat skin 
conditions. This species is also used in Mexico to manage diabetes (Andrade-Cetto and Heinrich, 
2005) and in vivo studies showed that its extracts have hypoglycaemic activity (Andrade-Cetto et al., 
2007; Nicasio et al., 2005) and would healing properties (Nayak, 2006).  
Tridax procumbens (L.) L. is a weed native to the tropical Americas. Animal studies showed that 
extracts of the leaves and of the whole plant have anti-diabetic and anti-hyperlipidaemic activity 
(Bhagwat et al., 2008; Pareek et al., 2009; Petchi et al., 2013). A pilot 4-week clinical study revealed 
that when administered to individuals with type 2 diabetes, an extract of the whole plant of T. 
procumbens (containing carotenoids, flavonoids and other phenolics) lowered blood glucose with no 
serious adverse effects reported (Desai et al., 2015). We also found a report of its use to treat kidney 
disease in El Salvador (Gonzalez-Ayala, 1994). This species is used traditionally in Nigeria as a 
treatment to reduce blood pressure and the findings of in vivo studies appear to supports this use 
(Salahdeen et al., 2004). 
Acosmium panamense (Benth.) Yakovlev is a tree naturally distributed in Mexico and in Central 
America (GBIF, 2015c). We found two sources reporting the use of A. panamense to manage 
diabetes in Belize (Balick and Arvigo, 2015; Ferrier, 2014). The use of this species in the management 
of diabetes was also reported in Mexico (Andrade-Cetto and Heinrich, 2005) and animal studies on 
the extracts of its bark showed hypoglycaemic activity (Andrade-Cetto and Wiedenfeld, 2004).   
Studies to investigate the hypoglycaemic chemical constituents of this species are lacking, although 
the bark does contain methoxylated quinolizidine alkaloids (Veitch et al., 1997), therefore safety 
would also need to be evaluated in addition to further studies on efficacy in diabetes. 
Quassia amara L. is a shrub growing in Central and South America (GBIF, 2015d). We found reports 
of its use to manage diabetes in Guatemala (Caceres et al., 1991) and in El Salvador (Gonzalez-Ayala, 
1994). The use of Q. amara to manage diabetes has also been documented in Suriname (Mans 2012) 
and among Suriname’s migrants in Holland (van Andel and Westers, 2010).  Animal studies showed 
antidiabetic activity of the extracts of this species (Husain et al., 2011; Ferreira et al., 2013), which 
included the observation of a hypoglycaemic effect with a standardised extract containing quassin, 
isoquassin and neoquassin (Husain et al., 2011); quassinoids are reported to act as insulin 
secretagogues (Husain et al., 2011). 
Artemisia absinthium L. is an herb native of the Mediterranean region. Animal studies found that 
extracts from this species have anti-hyperglycaemic activity (Daradka et al., 2014) and glucosidase 
and lipase inhibitory activities (Ramírez et al., 2012). The compounds responsible for these effects 
are yet to be investigated, although they are unlikely to be artemisinin derivatives, since these 
compounds have not been associated with hypoglycaemia (Davis, 1997). 
Catharanthus roseus (L.) G. Don is used to manage diabetes in several part of the world. In Central 
America we found reports of this use in Belize and in El Salvador (Balick and Arvigo, 2015; Gonzalez-
Ayala, 1994). Several animal studies showed that extracts from this species have a hypoglycaemic 
effect (Islam et al., 2009; Jayanthi et al., 2010; Mostofa et al., 2007; Nammi et al., 2003; Natarajan et 
al., 2012; Rasineni et al., 2010) and they reduce serum cholesterol and triglycerides (Antia et al., 
2005). An indole alkaloid, vindogentianine, from the leaves of this species was hypoglycaemic in vivo, 
an effect that was associated with enhanced glucose uptake and PTP-1B inhibition (Tiong et al., 
2015). Another alkaloid, vindoline, which occurs in the leaves of this species, improved glucose 
homeostasis in animal models of diabetes and it protected β-cell function from apoptosis (Yao et al., 
2013). These studies appear to provide some scientific basis to explain the traditional use of the 
leaves of this species for diabetes. 
Acrocomia aculeata (Jacq.) Lodd. ex Mart. is a 10-20 m tall palm. Animal studies conducted on this 
species showed the extract to have a hypoglycaemic effect (Perez et al., 1992) and a new 
tetrapyrane compound with hypoglycaemic activity was isolated from it (Pérez et al., 1997). Other 
studies on this species in relation to diabetes are lacking. 
Equisetum myriochaetum Schltdl. & Cham. is also widely used in Mexico to manage diabetes and to 
treat urinary problems (Andrade-Cetto and Heinrich, 2005). Animal studies of extracts of E. 
myriochaetum showed hypoglycaemic activity and the active constituents were suggested to be 
kaempferol glycosides and a caffeoyl glucoside (Cetto et al., 2000; Revilla et al., 2002). 
We found reports of the use of Hymenaea courbaril L., a tree found in Central America and South 
America, to treat kidney disease in Guatemala, Nicaragua and El Salvador (Kufer et al., 2005; Barrett, 
1994; Gonzalez-Ayala, 1994). Interestingly, Gupta reports that the infusion of the tea and leaves of 
H. courbaril has hypoglycemic activity (Gupta et al., 1979), although the compounds responsible are 
unknown.   
We found that a decoction of Pachira aquatica Aubl is used orally in Central America to treat kidney 
disease, urinary problems and skin conditions such as rashes and sores (Arnason et al., 1980; Balick 
and Arvigo, 2015; Coe, 2008; Coe et al., 1997; Coe and Anderson, 1996).  Although we did not find 
any report for the use of P. aquatica to manage diabetes in Central America, this use has been 
reported in at least 3 studies in Mexico (Hernandez-Galicia et al., 2002).  Currently, there is a lack of 
pharmacological and phytochemical studies investigating the anti-diabetic activity of this species.   
Similarly, a decoction of Desmodium adscendens (Sw.) DC. is used orally in Central America to treat 
skin conditions, kidney disease and urinary problems.  Although we did find any not direct evidence 
for the use of D. adscendens to manage diabetes, D. gangeticum (L.) DC. is used in ayurvedic 
traditional medicine for the management of diabetes and studies showed that this species has 
antidiabetic activity (Govindarajan et al., 2007). It is possible that other members of the genus 
Desmodium, including D. adscendens, could potentially produce mechanistic effects such as 
hypoglycaemia, thus this genus may be of interest to investigate further, from the ethnobotanical 
and pharmacological perspectives. 
 
We found 1 report of the use of Cocos nucifera L. (coconut) to manage diabetes in Central America 
(Barrett, 1994) along with reports for its use to treat cardiovascular disease, kidney disease and 
urinary problems (Balick and Arvigo, 2015; Girón et al., 1991; Gonzalez-Ayala 1994). There is some 
pharmacological evidence supporting the use of this species to manage diabetes and its sequelae: an 
extract of C. nucifera was anti-hyperglycaemic in vivo (Naskar et al., 2011); furthermore, coconut 
water showed beneficial effects on some biochemical parameters in diabetic rats (Preetha et al., 
2013) and consumption of coconut fibre from its flour is reported to decrease the glycaemic index of 
food (Trinidad et al., 2003).   
 
Girón et al (1991) reports the use of the leaf of Senna alata (L.) Roxb. to manage diabetes among the 
Caribs of Guatemala, and Balick and Arvigo (2015) reports the use of a decoction of the leaves and 
flowers of this species to treat kidney and urinary complaints in Belize. Moreover, several sources 
report the use of this species to treat skin infections, rashes and sores in Nicaragua (Coe 2008; Coe 
et al., 1997; Coe and Anderson, 1999; Coe and Anderson, 1996; Barrett 1994). Among the Miskitu of 
Nicaragua, the plant is also used to treat hypertension (Coe and Anderson, 1999). Animal studies of 
an extract of the leaves of this species showed an α-glucosidase inhibitory effect (Varghese et al., 
2013) and a hypoglycaemic effect in vivo (Palanichamy et al., 1988). The α-glucosidase inhibitory 
activity of the leaves has been attributed to kaempferol 3-O-gentiobioside (Varghese et al., 2013). 
Sambucus canadensis L. is used in Central America to treat kidney disease, urinary problems and skin 
conditions (Gonzalez-Ayala, 1994; MacVean, 2006; Nicolas 1999). There is a lack of studies 
supporting the traditional use of this species, except one study that found in vitro insulin-like actions 
of the related Sambucus nigra (Gray et al., 2000). Polyphenols from the fruit of the latter species 
have been associated with hypoglycaemic, hypolipidaemic and antioxidant effects in a rat model of 
diabetes (Ciocoiu et al., 2009). Extracts from the flowers of S. nigra, and the flower constituents α-
linolenic acid, linoleic acid and the flavanone naringenin, activate PPARγ and stimulate insulin-
dependent glucose uptake, indicating relevance for modulating insulin resistance (Christensen et al., 
2010). Other S. nigra flower constituents, notably ferulic, p-coumaric, caffeic acids, and kaempferol 
increased glucose uptake in vitro and reduced fat accumulation in Caenorhabditis elegans 
(Bhattacharya et al., 2013). Thus, investigations on the constituents of S. canadensis would be of 
interest to determine any mechanistic effects relevant to diabetes and to understand the 
phytochemicals responsible, enabling direct comparisons of biological properties of these two 
Sambucus species in relation to their traditional uses. 
 
Aloe vera (L.) Burm.f. is a widely used medicinal plant. In Central America we found one report of its 
use to manage diabetes in El Salvador (Gonzalez-Ayala, 1994) and reports as a treatment for skin 
conditions, and for kidney disease in Belize and El Salvador (Balick and Arvigo, 2015; Gonzalez-Ayala 
1994). This species is also used in Mexico to manage diabetes (Andrade-Cetto and Heinrich, 2005) 
and animal studies showed its extracts to have hypoglycaemic activity (Kim et al., 2009; Rajasekaran 
et al., 2005; Rajasekaran et al., 2004) and wound healing activity in diabetic rats (Chithra et al., 
1998).  Clinical trials concluded that A. vera juice is effective in lowering blood sugar and triglycerides 
in diabetes patients (Bunyapraphatsara et al., 1996; Yongchaiyudha et al., 1996), although more 
extensive RCTs are needed, which specifically investigate standardised extracts to enable firmer 
conclusions on efficacy to be determined. The biological activities of A. vera, including those relevant 
to diabetes and its sequelae, have been widely reviewed previously and recent updates on the 
biological effects and phytochemical constituents are described in Chinchilla et al. (2013). 
 
Eysenhardtia adenostylis Baill. is used among the Cakchiquels in Guatemala to treat diabetes (Cruz 
and Andrade-Cetto, 2015). We also found reports of its use to treat kidney disease, urinary problems 
and skin conditions in El Salvador and in Guatemala (Gonzalez-Ayala, 1994; MacVean, 2006).  These 
traditional uses may be associated with the antibacterial isoflavans that occur in this species (Hori et 
al., 2004), or due to other constituents with different modes of action which are yet to be 
elucidated. Interestingly, another species from Mexico, E. platycarpa Pennell & Saff., is used 
traditionally for kidney and bladder infections and for complications of diabetes (Naváez-Mastache 
et al., 2006). One of the major components isolated from the branches and leaves of the latter 
species, 3-O-acetyloleanolic acid, decreased body weight and glucose level in streptozotocin-induced 
diabetic rats (Naváez-Mastache et al., 2006). 
 
A decoction of the styli of Zea mays L. is used orally in Guatemala, Belize and El Salvador to treat 
kidney disease and urinary problems (Balick and Arvigo, 2015; Girón et al., 1991; Gonzalez-Ayala, 
1994; Kufer et al., 2005). In Mexico this preparation is also used to manage diabetes (Andrade-Cetto 
et al., 2006; Andrade-Cetto and Heinrich, 2005). Accordingly, Suzuki et al. (2005) showed a positive 
effect of the style of this species on streptozotocin-induced diabetic nephropathy (Suzuki et al., 
2005). The flavones, chrysoeriol 6-C-β-boivinopyranosyl-7-O-β glucopyranoside and chrysoeriol 6-C-
β-L-boivinopyranoside, have been isolated from the style of this species, and they exhibited 
glycation inhibitory activity (Suzuki et al., 2003), which provides some scientific explanation for the 
traditional use for diabetes in Mexico. 
 
In Belize a decoction of the bark of Guazuma ulmifolia Lam. is consumed orally to manage diabetes  
and treat urinary problems and it is used externally to treat skin sores and infections (Balick and 
Arvigo, 2015). This species is also used in Panama to treat kidney disease (Duke, 1986) and in 
Honduras to treat urinary problems (Lentz et al., 1998). In Mexico an infusion of the bark of G. 
ulmifolia is used to treat type-2 diabetes (Andrade-Cetto and Heinrich, 2005) and extracts of this 
species have been found to lower plasma glucose in animal studies (Alarcon-Aguilara et al., 1998). 
There are limited published data on the phytochemical constituents that might mediate the 
observed pharmacological effects of this species. 
We found reports of the use of Piper auritum Kunth in Central America to manage diabetes and to 
treat cardiovascular disease, kidney disease and skin conditions (Balick and Arvigo, 2015; Barrett, 
1994; Coe, 2008; Ferrier, 2014; House and Sanchez, 1997).  A pharmacological study found that an 
extract of this species has antidiabetic effects (Gutierrez, 2012) and the results of an in vitro and in 
vivo study suggest that this species prevents oxidative stress and renal damage associated with 
diabetes (Perez Gutierrez et al., 2012). This species also requires further study to elucidate the 
biologically active constituents relevant to diabetes and the traditional uses.  
Jatropha curcas L.  is a large shrub widely used in traditional medicine in Central and South America, 
Africa, Asia and Middle East (Abdelgadir and Van Staden, 2013). We found reports of the use of this 
species to treat urinary problems and skin conditions in Guatemala, Belize, and El Salvador (Balick 
and Arvigo, 2015; Girón et al., 1991; Gonzalez-Ayala, 1994). Animal studies showed that the extract 
of the leaf and root of this species has hypoglycaemic activity, and it reduced cholesterol and 
triglyceride levels (Mishra et al., 2010; Muhammad 2013) and has wound healing properties  
(Esimone et al., 2008; Shetty et al., 2006; Villegas et al., 1997). Igbinosa et al. (2011) concluded the 
polyphenols were important for bioactivity. The anti-diabetic effects of the leaves of this species, 
including hypoglycaemic and antioxidant effects observed in streptozotocin-induced diabetic rats, 
are suggested to be associated with the flavonoids rhoifolin, isoorientin and isoquercetrin (El-Baz et 
al., 2014). This species is associated with anti-inflammatory, antimicrobial  and antioxidant activities 
(Abdelgadir and Van Staden, 2013).  
 
4 Conclusion 
In this review we found that out of 105 species reported to be used to manage diabetes in Central 
America, only seven species are reported 3 or more times while 84 other species are reported in just 
one study. Similarly to what has been observed for the distribution of overall medicinal plant 
knowledge (Barrett, 1995), it seems that the shape of the distribution of knowledge of medicinal 
plants used to manage diabetes has a “long tail”. Some pharmacological studies provide some 
scientific basis to explain the traditional uses of the species with at least 3 independent reports. 
Extracts from many of these species showed hypoglycaemic effects in animal models of diabetes. 
However, in many cases the specific mechanisms and the active compounds causing this effect are 
unknown and there is a lack of RCTs for most of the species.     
There are many challenges associated with understanding the use of plants as medicines. Knowledge 
of the traditional uses, the plant parts used, the preparations and the routes of administration can 
be multiple and complex for one species. Furthermore, robust studies to understand any scientific 
basis to explain recorded traditional uses are often lacking. Although many studies describe 
pharmacological activities in vitro and/or in vivo that may provide some scientific basis to explain a 
traditional use relevant to diabetes, additional complexities such as the method(s) of preparation, 
the route of administration encompassing bioavailability and pharmacokinetics and dose are often 
not considered. Therefore for many species, more scientific research is needed to understand any 
pharmacological basis that might explain traditional uses, and also the sustainable and appropriate 
uses of plants as medicines. One of the major challenges for research on plants as medicines is the 
lack of available chemically-characterised and standardised preparations for investigation, 
particularly in RCTs, but also for many pharmacological studies. These issues were also observed for 
the main recorded species in this study, in relation to the scientific basis for their use in diabetes. 
More scientific studies are therefore needed to understand the pharmacological effects of species 
used traditionally for diabetes, which are directly correlated with chemically-characterised extracts. 
For those species where pharmacological studies are most promising to modulate parameters of 
diabetes, more robust clinical studies, also investigating standardised extracts, are needed to 
understand efficacy from both the traditional use and potential use perspectives. Indeed, even one 
of the most widely studied species relevant to diabetes (in previous studies and one of the most 
reported species in the present study), Momordica charantia, when evaluated in a Cochrane Review 
it was revealed that there were issues with the quality of clinical trial data and methods were flawed 
due to the variability of preparations of this plant used in the interventions; thus it was concluded 
that there was no significant change in reliable parameters of glycaemic control, compared to the 
diabetes drugs, metformin and glibenclamide (Ooi et al., 2012). 
The approach used in this study was to investigate both the medicinal plants reported for the 
management of diabetes and its sequelae. By using this approach we provided a more complete 
view on the use of medicinal plant species to manage diabetes in Central America than by looking 
only at the species reported for the management of diabetes. Interestingly, several of the species 
that are used to manage diabetes in Central America are also used to treat conditions that may arise 
as consequence of diabetes such as kidney disease, urinary problems and skin conditions. The 
contemporaneous presence of many phytochemicals with potentially multiple biological activities it 
is often a hallmark of the practice of phytotherapy. For example, the leaves of Neurolaena lobata are 
widely used both to manage diabetes and to treat skin conditions. In the case of the use of medicinal 
plants to treat a metabolic disorder such as diabetes, we suggest that it is useful to use a syndromic 
approach that includes the multiple uses of plant species for conditions and symptoms related to 
diabetes, and investigate how these uses relate to their phytochemical and biological activities. 
Accordingly, McCune and Johns (2002 and 2003) looked at the anti-oxidant properties of species 
used in the treatment of symptoms of diabetes among the peoples of the boreal forest of Eastern 
Canada and Leduc et al. (2006) developed a quantitative methodology to identify species with anti-
diabetic properties that takes in account the use of species in the treatment of symptoms of 
diabetes. 
The value of these medicinal plants and their associated knowledge may have relevance in the 
potential drug development in the future, but they are also of value for their present use among the 
population of Central America. Considering the huge economic cost of diabetes to both individuals 
and society in Central American countries (Barcelo et al., 2013), that only few countries have full 
coverage for diabetics in the formal healthcare system (Aschner et al., 2014), and that the risk of 
developing type2 diabetes is associated with a low socio-economic position (Agardh et al., 2011), it is 
important to highlight and understand any effective plant remedies to manage diabetes, and the 
associated local knowledge, to assist with providing a valuable, cost-effective, sustainable and 
culturally appropriate health care service to the population of Central America.   
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DM: Animal studies showed hypoglycaemic effect 
(Harinantenaina et al., 2006; Reyes et al., 2006; Sathish 
et al., 2005; Shetty et al., 2005).  
SI: Several studies showed evidence that this species has 
broad-spectrum anti-microbial activity (Grover and 
Yadav, 2004; Ooi et al., 2010).  
Spe
cie
s 
use
d 
to 
ma
nag
e 
dia
bet
es  
D
M 
C
D 
K
D 
S
I 
U
P 
V
L 
T
o
t
a
l 
C
o
u
n
t
r
y  
P
l
a
n
t 
p
a
r
t 
M
o
d
e
 
o
f 
u
s
e 
Evidence  
Ne
ur
ola
en
a 
lob
at
a 
(L.) 
R.B
r. 
ex 
Ca
ss. 
(As
ter
ac
ea
e) 
6   1
2 
  1
8 
B
E
, 
G
U
, 
N
I 
L
f 
I
n
t
.  
DM: leaf extracts decrease significantly blood glucose in 
mice (Aguilar Santa-Maria et al., 2009; Gupta et al., 1984) 
SI : antimicrobial activity (Nayak et al., 2014). Extract 
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et al., 2014; Walshe-Roussel et al., 2013) 
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 DM: extracts have hypoglycaemic properties on animal 
models (Román-Ramos et al., 1990) 
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 DM: Hypoglycaemic properties have been shown in 
animal studies   (Antia et al., 2005; Brai et al., 2007; 
Ezejiofor et al., 2013; Gondwe et al., 2008) 
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DM: extracts have hypoglycaemic properties on animal 
models (Mukhtar et al., 2004; Mukhtar et al., 2006; Oh et 
al., 2005; Ojewole 2005; Shen et al.,2008) 
SI: antimicrobial and analgesic and anti-inflammatory 
properties (Gutiérrez et al., 2008). 
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DM: extracts have hypoglycaemic and anti-inflammatory 
effect on animal models  (Esimone et al., 2001; Ojewole, 
2003; Olatunji et al., 2005; Sokeng et al., 2001) 
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DM: one study suggests that the extract of this species 
have hypoglycaemic properties (Pandurangan et al., 
2013). Extracts have anti-microbial (Camporese et al., 
2003), anti-inflammatory (Sosa et al., 2002) and some 
wound healing activity (Gomez-Beloz et al., 2003).      
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DM: Also used in Mexico to manage diabetes (Andrade-
Cetto and Heinrich, 2005); Animal studies showed anti-
microbial, anti-inflammatory activity of the extracts 
(Camporese et al., 2003; Bork et al., 1996; Sosa et al., 
2002; Noguera et al., 2004)  
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DM and SI:  Extracts have hypoglycaemic, hypolipidaemic 
and wound healing activities (Maniyar and 
Bhixavatimath, 2012; Adeneye et al., 2009; Juárez-Rojop 
et al., 2012; Sasidharan et al., 2011) 
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DM: Extracts can have both hypoglycaemic or 
hyperglycaemia-inducing activity depending on how the 
extract is prepared (Morrison et al., 1990; Quanico et al., 
2008; Russell et al., 2008) and a hypolipidaemic effect 
(Ferreira et al., 2013).  
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DM: Extracts have hypoglycaemic effect (Andrade-Cetto 
and Wiedenfeld, 2001; Herrera-Arellano et al., 2004; 
Pérez-Guerrero et al., 2001; Revilla-Monsalve et al., 
2007; Román-Ramos et al., 1990) 
A clinical trial showed beneficial effects of an extract of 
this species administered as an adjunct on type-2 
diabetes patients (Herrera-Arellano et al., 2004).  
Hypoglycaemic effect on type 2 diabetic patients (Revilla-
Monsalve et al., 2007). 
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DM:  extracts of the leaves and of the whole plant have 
antidiabetic and anti-hyperlipidemic activity (Bhagwat et 
al., 2008; Pareek et al., 2009; Petchi et al., 2013) 
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DM: Animal studies of the extract showed hypoglycaemic 
activity (Andrade-Cetto and Wiedenfeld, 2004)  
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DM: Animal studies showed antidiabetic activity of the 
extracts of this species (Ferreira et al., 2013; Husain et 
al., 2011)  
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 No evidence for DM( 
(note: no data about the content of aristolochic acids, 
potentially toxic) 
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DM: Extract of this species has antihyperglycaemic 
activity on animals (Daradka et al., 2014). Extract has in 
vitro glucosidae and lipase inhibitory activities (Ramírez 
et al., 2012).   
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DM: Extracts have in vivo hypoglycaemic effect (Islam et 
al., 2009; Jayanthi et al., 2010; Mostofa et al., 2007; 
Nammi et al., 2003; Natarajan et al., 2012; Rasineni et al., 
2010) and reduce serum cholesterol and triglycerides 
(Antia et al., 2005). 
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DM: Extract has in vivo hypoglycaemic effect (Pérez et al., 
1997; Perez et al., 1992) 
Table 1. Medicinal species used to manage diabetes reported in at least 2 sources.  
Species used to manage diabetes: The Plant List full accepted name and family (in bold) 
Country: Ni=Nicaragua, GU=Guatemala, BE=Belize, SA=El Salvador, CR=Costa-Rica, PA=Panama.  
Reports from different sources by disease category: DM= Diabetes, CD= Cardiovascular disease, 
KD= Kidney disease, SI= Skin conditions, UP= Urinary Problems, VL: Vision loss. Total= total of 
reports for all the disease categories considered 
Plant part: Lf= leaf, St= stem, Ba= Bark, Se= Seed, Ro= root, Fw= flower, Fr= fruit. ; Mode of use: 
Int.= internal (oral), ext= external (topic) 
 
 
Species used to treat skin 
conditions  
 
Family Country Parts 
used 
Mode 
of 
use 
Sources 
Neurolaena lobata (L.) R.Br. ex 
Cass. 
Asteraceae NI, BE, GU, 
PA 
leaf ext. & 
int.  
12 
Carica papaya L. Caricaceae BE, PA, SA, 
NI 
latex, 
leaf, 
fruit, 
bark 
ext. 8 
Acalypha aristata Kunth Euphorbiaceae NI, GU, BE leaf, 
whole 
plant, 
bark, 
sap 
ext. & 
int.  
7 
Psidium guajava L. Myrtaceae NI, GU, BE bark, 
fruit, 
leaf 
ext. & 
int.  
6 
Cassia grandis L.f. Fabaceae BE, NI fruit, 
leaf, 
stem, 
root 
ext. & 
int.  
6 
Bursera simaruba (L.) Sarg. Burseraceae GU, NI, BE bark, 
leaf 
ext. & 
int.  
5 
Momordica charantia L. Cucurbitaceae NI, GU, BE leaf , 
stem 
ext. & 
int.  
5 
Anacardium occidentale L. Anacardiaceae NI bark, 
leaf 
ext. & 
int.  
5 
Hamelia patens Jacq. Rubiaceae BE, NI, SA leaf, 
whole 
plant, 
flower 
ext. & 
int.  
5 
Passiflora quadrangularis L. Passifloraeae NI, PA leaf, 
stem 
ext. & 
int.  
5 
Senna alata (L.) Roxb. Fabaceae NI leaf, 
fruit, 
flower 
ext. & 
int.  
5 
Bryophyllum pinnatum (Lam.) 
Oken 
Crassulaceae NI, GU, BE leaf ext. 5 
Commelina erecta L. Commelinaceae BE, NI leaf 
and 
stem 
ext. & 
int.  
5 
Cordia alliodora (Ruiz & Pav.) 
Oken 
Boraginaceae BE, NI Seed, 
leaf 
ext. & 
int.  
5 
Heliotropium indicum L. Boraginaceae BE, NI leaf, 
whole 
plant 
ext. & 
int.  
5 
Species used to treat skin 
conditions  
 
Family Country Parts 
used 
Mode 
of 
use 
Sources 
Mangifera indica L. Anacardiaceae NI bark, 
fruit, 
leaf 
ext. & 
int.  
5 
Rhizophora mangle L. Rhizophoraceae BE, NI bark ext. & 
int.  
5 
Spondias mombin L. Anacardiaceae BE, NI bark, 
leaf 
ext. & 
int.  
5 
Spondias purpurea L. Anacardiaceae NI, BE, SA bark, 
leaf 
ext. & 
int.  
5 
Desmodium adscendens (Sw.) 
DC. 
Fabaceae NI leaf, 
whole 
plant, 
root 
int. 4 
Hyptis verticillata Jacq. Lamiaceae NI leaf, 
whole 
plant, 
root 
ext. & 
int.  
4 
Lygodium venustum Sw. Lygodiaceae BE, NI leaf ext. 4 
Dysphania ambrosioides (L.) 
Mosyakin & Clemants 
Amaranthaceae GU, NI, BE whole 
plant, 
leaf 
ext. 4 
Lantana camara L. Verbenaceae BE, PA,GU, 
NI 
leaf ext. 4 
Xiphidium caeruleum Aubl. Haemodoraceae BE, NI, PA leaf ext. & 
int.  
4 
Capsicum annuum var. 
glabriusculum (Dunal) Heiser & 
Pickersgill 
Solanaceae NI seed, 
fruit, 
leaf, 
flower 
ext. & 
int.  
4 
Capsicum chinense Jacq. Solanaceae NI seed, 
fruit, 
leaf, 
flower 
ext. & 
int.  
4 
Coccoloba uvifera (L.) L. Polygonaceae NI bark, 
leaf 
int. 4 
Gynerium sagittatum (Aubl.) 
P.Beauv. 
Poaceae NI root int. 4 
Manilkara zapota (L.) P.Royen Sapotaceae NI stem, 
sap 
ext. 4 
Oryza sativa L. Poaceae NI seed, 
stem 
ext. & 
int.  
4 
Pentaclethra macroloba 
(Willd.) Kuntze 
Fabaceae NI bark ext. & 
int.  
4 
Species used to treat skin 
conditions  
 
Family Country Parts 
used 
Mode 
of 
use 
Sources 
Piper peltatum L. Piperaceae NI, GU, BE, 
HO 
leaf Ext.    4 
Senna reticulata (Willd.) 
H.S.Irwin & Barneby 
Fabaceae Ni leaf, 
root 
int. 4 
Simarouba amara Aubl. Simaroubaceae BE, NI, GU leaf, 
fruit, 
bark, 
seed 
ext. & 
int.  
4 
Solanum lycopersicum L. Solanaceae NI leaf ext. 4 
Struthanthus cassythoides 
Millsp. ex Standl. 
Loranthaceae BE, NI leaf, 
whole 
plant 
ext. & 
int.  
4 
Theobroma cacao L. Sterculiaceae NI seed, 
leaf 
ext. 4 
Cecropia peltata L. Urticaceae NI, BE, HO leaf ext. & 
int.  
3 
Pachira aquatica Aubl. Bombacaceae Ni bark int. 3 
Piper auritum Kunth Piperaceae NI, Ho, BE leaf ext. & 
int.  
3 
Coix lacryma-jobi L. Poaceae NI seed, 
root 
int. 3 
Bixa orellana L. Bixaceae NI, BE, HO leef, 
seed 
ext. & 
int.  
3 
Jatropha gossypiifolia L. Euphorbiaceae NI leaf int. 3 
Psychotria poeppigiana 
Müll.Arg. 
Rubiaceae NI fruit, 
leaf, 
stem, 
root 
ext. & 
int.  
3 
Byrsonima crassifolia (L.) Kunth Malpighiaceae BE, GU, NI bark, 
leaf 
ext. & 
int.  
3 
Cuscuta americana L. Convolvulaceae NI leaf, 
stem 
ext. 3 
Dalbergia brownei (Jacq.) Urb. Fabaceae NI bark, 
leaf, 
stem 
ext. & 
int.  
3 
Desmodium barbatum (L.) 
Benth. 
Fabaceae NI leaf, 
root 
int. 3 
Gliricidia sepium (Jacq.) Walp. Fabaceae BE, NI bark, 
leaf 
ext. & 
int.  
3 
Hamelia rovirosae Wernham Rubiaceae BE, NI fruit, 
leaf, 
stem, 
ext. & 
int.  
3 
Species used to treat skin 
conditions  
 
Family Country Parts 
used 
Mode 
of 
use 
Sources 
root 
Hiraea quapara (Aubl.) Sprague Malpighiaceae NI leaf ext 3 
Ipomoea mauritiana Jacq. Convolvulaceae NI leaf ext. & 
int.  
3 
Ipomoea pes-caprae (L.) R. Br. Convolvulaceae NI leaf ext. & 
int.  
3 
Jatropha curcas L. Euphorbiaceae BE, GU, SA leaf, 
latex 
ext. 3 
Mucuna sloanei Fawc. & 
Rendle 
Fabaceae NI sap ext. 3 
Olyra latifolia L. Poaceae NI leaf, 
root 
ext. & 
int.  
3 
Pouteria sapota (Jacq.) 
H.E.Moore & Stearn 
Sapotaceae NI bark, 
leaf, 
seed 
ext. & 
int.  
3 
Saccharum officinarum L. Poaceae NI leaf, 
stem 
ext. & 
int.  
3 
Smilax spinosa Mill. Smilacaceae NI, GU, BE, 
HO 
root ext. & 
int.  
3 
Solanum torvum Sw. Solanaceae BE, NI leaf, 
root 
ext. 3 
Spermacoce laevis Lam. Rubiaceae PA, NI leaf, 
whole 
plant 
ext. 3 
 
Table 2 Plants used to treat skin conditions 
Species used to treat skin conditions: The Plant List full accepted name ; Country: Ni= Nicaragua, 
GU= Guatemala, BE= Belize, SA= El Salvador, CR=Costa-Rica, PA= Panama. ; Mode of use: int.= 
internal (oral), ext= external (topic) ; Sources: number of sources where the species was reported for 
the treatment of skin conditions 
 
 
Species used to 
treat kidneys 
disease            
 
Family  Country Parts used Mode of use Sources 
Bursera simaruba 
(L.) Sarg. 
Burseraceae  BE, GU, 
PA  
leaf, bark, fruits int. 4 
Equisetum 
myriochaetum 
Schltdl. & Cham. 
Equisetaceae  GU, SA Aerial part, whole  int. 3 
Hymenaea Fabaceae  GU, SA, Bark, leaf int. 3 
courbaril L. NI 
Sambucus 
canadensis L. 
Adoxaceae  GU, SA Flower, bark, leaf int. 3 
Aloe vera (L.) 
Burm.f. 
Liliaceae  SA, BE leaf, gel int. 2 
Cecropia peltata L. Urticaceae  SA, BE leaf, bark int. 2 
Cocos nucifera L. Arecaceae  SA, BE water from fruit int. 2 
Eysenhardtia 
adenostylis Baill. 
Fabaceae  SA, GU stem, bark int. 2 
Pachira aquatica 
Aubl. 
Bombaceae  BE seed, fruit int. 2 
Zea mays L. Poaceae  BE, SA styli int. 2 
 
Table 3 Plants used to treat kidneys disease 
Species used to treat kidney disease: The Plant List accepted full name; Country: Ni= Nicaragua, 
GU= Guatemala, BE= Belize, SA= El Salvador, CR=Costa-Rica, PA= Panama. ; Mode: int= internal 
(oral), ext=external (topic); Sources: number of sources where the species was reported for the 
treatment of kidney disease 
 
 
Species used to treat 
urinary problems  
 
Family Country Parts 
used 
Mode of use Sources 
Zea mays L. Poaceae BE, SA, 
GU 
styli Int. 5 
Arthrostemma 
ciliatum Pav. ex D. Don 
Melastomataceae PA, BE, 
HO, CR 
stem, 
whole 
plant 
int. 4 
Cocos nucifera L. Arecaceae BE, SA, 
GU 
water 
from 
fruit 
int. 3 
Acalypha aristata 
Kunth 
Euphorbiaceae GU, BE whole int. 2 
Bursera simaruba (L.) 
Sarg. 
Burseraceae PA, GU bark, 
fruits 
int. 2 
Jatropha curcas L. Euphorbiaceae BE, SA leaf, bark int. 2 
Equisetum 
myriochaetum Schltdl. 
& Cham. 
Equisetaceae SA, GU whole int. 2 
Guazuma ulmifolia 
Lam. 
Malvaceae BE, HO bark int. 2 
Euphorbia hirta L. Euphorbiaceae BE, GU leaf, bark int. 2 
Capraria biflora L. Scrophulariaceae BE, GU leaf, bark int. 2 
Passiflora coriacea 
Juss. 
Passifloraceae SA, GU leaf  int. 2 
Table 4 Plants used to treat urinary problems 
Species used to treat urinary problems: The Plant List full accepted name ; Country: Ni= Nicaragua, 
GU= Guatemala, BE= Belize, SA= El Salvador, CR=Costa-Rica, PA= Panama. ; Mode of use: 
int=internal (oral), ext=external (topic) ; Sources: number of sources where the species was reported 
for the treatment of urinary problems 
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